Bioxytran, Inc. (BIXT)

OTCMKTS · Delayed Price · Currency is USD
0.1500
+0.0075 (5.26%)
Apr 1, 2025, 3:36 PM EST
41.78%
Market Cap 12.44M
Revenue (ttm) n/a
Net Income (ttm) -2.70M
Shares Out 88.13M
EPS (ttm) -0.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 48,710
Average Volume 562,731
Open 0.1350
Previous Close 0.1425
Day's Range 0.1288 - 0.1500
52-Week Range 0.0615 - 0.2060
Beta 1.00
RSI 51.97
Earnings Date Mar 28, 2025

About Bioxytran

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 3
Stock Exchange OTCMKTS
Ticker Symbol BIXT
Full Company Profile

Financial Performance

Financial Statements

News

Bioxytran Signs NDA with the University of Georgia to Evaluate Galectin Antagonists for Bird Flu Treatment in Chickens

In Vitro studies have shown promise against viruses similar to the bird flu virus BOSTON, MASSACHUSETTS, March 19, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical st...

13 days ago - GlobeNewsWire

Bioxytran Develops a Groundbreaking Treatment to Combat Bird Flu in Egg Laying Chickens Potentially Saving Billions

New water-soluble galectin antagonist being considered in preclinical trials offering hope for rapid containment to H5N1 outbreaks

20 days ago - GlobeNewsWire

Bioxytran's Cancer Preprint Reveals Potential to Enhance Most Immunotherapy Drugs

BOSTON, MASSACHUSETTS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral dise...

2 months ago - GlobeNewsWire

Bioxytran's Medical Breakthrough in Fighting All Viruses

Breakthrough was validated in the latest journal article Galectins are essential for viral entry and a new target for drug development Carbohydrates were shown to neutralize viruses Blocking galectins...

6 months ago - Accesswire

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

MIAMI, Aug. 20, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 74th Emerging Growth Conference on August 21 – 22, 2024.

8 months ago - GlobeNewsWire

Bioxytran Launches Joint Venture with the Heme Foundation for Development of Universal Oxygen Carrier

The Heme Foundation and Bioxytran join forces to address the global blood supply shortage BOSTON, MASSACHUSETTS, July 18, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clin...

9 months ago - GlobeNewsWire

Bioxytran's Advisor Releases Book on Hyperbaric Oxygenation Related to Stroke & Alzheimer's Patients

BXT-25 is expected to oxygenate the brain BOSTON, MASSACHUSETTS, June 27, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing drug...

9 months ago - GlobeNewsWire

Bioxytran Announces Preprint of Shingles Case Study Showing Clearance Using a Topical Galectin-3 Antagonist

50% Lesion clearance and regression of Herpes Zoster Neuralgia within 48 – 72 hours BOSTON, MASSACHUSETTS, March 06, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage ...

1 year ago - GlobeNewsWire

Bioxytran's Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19

First Medicinal chemistry of an antiviral drug made of sugars BOSTON, MASSACHUSETTS, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB:  BIXT), (the “Company”), a clinical stage biotechnology ...

1 year ago - GlobeNewsWire

Bioxytran Gets Broad Patent Coverage on 60+ Viruses

Claims cover method of treating a viral infection with a lectin-binding carbohydrate BOSTON, MASSACHUSETTS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage ...

1 year ago - GlobeNewsWire

Bioxytran Interview at the Emerging Growth Conference

BOSTON, MASSACHUSETTS, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 a...

1 year ago - GlobeNewsWire

Bioxytran Announces Broad Spectrum Antiviral Activity Highlighted in ProLectin-M

BOSTON, MASSACHUSETTS, Sept. 14, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral diseas...

1 year ago - GlobeNewsWire

Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials

BOSTON, MASSACHUSETTS, Aug. 24, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral disease...

1 year ago - GlobeNewsWire

Bioxytran Initiates a Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID-19 Patients

BOSTON, MASSACHUSETTS, Aug. 08, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral disease...

1 year ago - GlobeNewsWire

Bioxytran Names Leslie Ajayi as Interim CMO and Head of the Medical Advisory Board

BOSTON, MASSACHUSETTS, July 31, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral disease...

1 year ago - GlobeNewsWire

Bioxytran Peer-Reviewed Journal in “Vaccines” Contains Mechanism Capable of Targeting Future COVID-19 Mutations

Complete elimination of viral load in 100% of patients at day 7 vs 6% in placebo (p=.001) Complete elimination of most symptoms by day 7 Galectin antagonist acts as an entry inhibitor for use in treat...

1 year ago - GlobeNewsWire

Bioxytran Expands Institutional Investor Base with an additional $500,000 Equity Investment

- Funding in place to meet next regulatory milestone BOSTON, MASSACHUSETTS, June 12, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing...

1 year ago - GlobeNewsWire

Bioxytran Tests Acellular Oxygen Carrier BXT-25 in Pre-Clinical Trials

BOSTON, MASSACHUSETTS, April 19, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral diseas...

2 years ago - GlobeNewsWire

Bioxytran Announces Positive Phase 2 Trial Results were Featured in “Vaccines” a Peer-Reviewed Journal

Complete elimination of viral load in 100% of patients at day 7 vs 6% in placebo (p=.001) Complete elimination of most symptoms by day 7 Galectin antagonist acts as an entry inhibitor for use in treat...

2 years ago - GlobeNewsWire

ProLectin-M Demonstrates Significant Activity Against Influenza and Respiratory Syncytial Virus

Activity in Influenza and Respiratory Syncytial Virus highlights the broad - spectrum antiviral potential of ProLectin-M

2 years ago - GlobeNewsWire

Nature Reviews Drug Discovery Article Offers Independent Support for ProLectin-I in Fibrosis and ProLectin-M as an Antiviral Drug

BOSTON, MASSACHUSETTS, Feb. 22, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19, ...

2 years ago - GlobeNewsWire

Bioxytran to Appear on ClearThink IR's Virtual Live Event

- Wednesday, February 15th , 202 3 12 : 00 EST

2 years ago - GlobeNewsWire

Bioxytran Receives Approval to Initiate Trials with ProLectin-I

BOSTON, MASSACHUSETTS, Feb. 06, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 a...

2 years ago - GlobeNewsWire

Crystal Research Update Highlights 100% Responders Rate in Mild to Moderate COVID-19 Trial

BOSTON, MASSACHUSETTS, Dec. 28, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 a...

2 years ago - GlobeNewsWire

Bioxytran Establishes Indian Subsidiary in Preparation of Commercialization

BOSTON, MASSACHUSETTS, Dec. 14, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 a...

2 years ago - GlobeNewsWire